Inspire Medical’s Upper Airway Stimulator Impresses FDA Panel
This article was originally published in The Gray Sheet
FDA’s Anesthesiology and Respiratory Devices Panel endorsed Inspire Medical Systems’ PMA for the Inspire upper airway stimulation system at a Feb. 20 meeting. Inspire is intended for patients with sleep apnea who have not responded to continuous positive airway pressure therapy.
You may also be interested in...
FDA panel unanimously endorses Inspire upper airway stimulator. Stryker buys Berchtold and Pivot. First randomized U.S. study of embolic protection during transcatheter aortic valve replacement approved. More news.
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.